OpenNeedle Ask your own

Question explored with the scientific record

Will ivermectin and Fenbendazole help lymphoma?

Aug 31, 2026 · 13 sources examined · OpenNeedle synthesis
The short version: the evidence does not show that ivermectin or fenbendazole improves lymphoma outcomes in humans.

The retrieved evidence contains no clinical trial, no case series, and no human study testing either drug against lymphoma. What exists is a 1997 review of anthelmintic mechanisms [13] that describes how benzimidazoles (fenbendazole's class) disrupt microtubules by binding β-tubulin in parasites. That is a plausible anticancer mechanism in theory—microtubule poisons are used in chemotherapy—but the review is about worms, not cancer cells, and it cites no lymphoma data.

The same review notes that ivermectin opens glutamate-gated chloride channels in parasites [13], a target that human cells do not express in the same way. A separate 2015 veterinary study found ivermectin inhibits feline P-glycoprotein [1], a drug efflux pump that can make chemotherapy less effective. That is a mechanism that could interfere with standard lymphoma treatment, not help it. Neither study tested lymphoma cells or tumor growth.

The rest of the evidence covers unrelated drugs: sorafenib, lactoferricin, HDAC inhibitors, proteasome inhibitors, CD40L, and triterpenoids [2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]. None of these are ivermectin or fenbendazole. They show that lymphoma cells can be killed in lab dishes and mice by various experimental compounds, but that tells you nothing about whether a dewormer will work.

My call: there is no human evidence that ivermectin or fenbendazole helps lymphoma. The proposed mechanisms are speculative and drawn from parasite biology, not cancer biology. Confidence: high that the evidence does not support use.

Keep digging

Sources examined 13

  1. A functional model for feline P‐glycoprotein Journal of Veterinary Pharmacology and Therapeutics (2015) Thin

    This study establishes a functional assay using fluorescence-associated flow cytometry to measure the inhibitory potential of various veterinary drugs on feline P-glycoprotein, revealing that PSC833 and ivermectin are the most potent inhibitors, while several other tested drugs …

    DOI: 10.1111/jvp.12248
  2. Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis Leukemia Research (2010) primary study Strong

    MEK1/2 inhibition markedly potentiates sorafenib-induced apoptosis in diverse lymphoma cell lines, with synergy linked to rapid Mcl-1 down-regulation and not requiring Bim up-regulation.

    DOI: 10.1016/j.leukres.2009.07.013
  3. Bovine lactoferricin induces caspase-independent apoptosis in human B-lymphoma cells and extends the survival of immune-deficient mice bearing B-lymphoma xenografts Experimental and Molecular Pathology (2010) primary study Strong

    LfcinB induces caspase-independent apoptosis in human B-lymphoma cells and extends survival in SCID/beige mice bearing disseminated Ramos B-lymphoma xenografts.

    DOI: 10.1016/j.yexmp.2010.02.001
  4. HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells Apoptosis (2011) Thin

    This study investigates the synergistic apoptotic effects of enzastaurin, a PKC beta inhibitor, in combination with histone deacetylase (HDAC) inhibitors on lymphoma cells, demonstrating enhanced cytotoxicity and potential therapeutic strategies for lymphoid malignancies.

    DOI: 10.1007/s10495-011-0617-x
  5. Peptidyl Aldehyde Inhibitors of Proteasome Induce Apoptosis Rapidly in Mouse Lymphoma RVC Cells Journal of Biochemistry (1997) Thin

    This study investigates the role of proteasome inhibitors in inducing apoptosis in mouse lymphoma RVC cells, demonstrating that these inhibitors cause cell cycle arrest at the G2/M phase and subsequent apoptotic changes, including DNA fragmentation and deubiquitination of histon…

    DOI: 10.1093/oxfordjournals.jbchem.a021620
  6. Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex Blood (2013) Thin

    Cell-surface nucleolin binds Fas and blocks FasL binding to prevent Fas-mediated apoptosis in B-cell lymphomas; nucleolin knockdown increases Fas sensitivity while nucleolin overexpression protects mice from Fas-induced liver injury, identifying surface nucleolin as a potential …

    DOI: 10.1182/blood-2012-12-471094
  7. Induction of Apoptosis in B Lymphoma Cells by Activation with CD40L Acta Haematologica (2000) Thin

    This study investigates the induction of apoptosis in B lymphoma cells through activation with CD40L, demonstrating significant increases in costimulatory molecule expression and apoptosis rates in certain B lymphoma cell lines.

    DOI: 10.1159/000041042
  8. Triterpenoids Display Single Agent Anti-tumor Activity in a Transgenic Mouse Model of Chronic Lymphocytic Leukemia and Small B Cell Lymphoma PLoS ONE (2007) Thin

    This study demonstrates that the synthetic triterpenoids CDDO and its derivative CDDO-Im exhibit significant anti-tumor activity against chronic lymphocytic leukemia (CLL) and small B cell lymphoma (SBL) in a transgenic mouse model, with CDDO-Im being notably more potent than CD…

    DOI: 10.1371/journal.pone.0000559
  9. 261 Variations of genes related with skin barrier or immune response in the patients with atopic dermatitis could be simultaneously and rapidly detected on a membrane for reverse blot hybridization assay Journal of Investigative Dermatology (2016) Thin

    This study investigates the expression of the c-CBL E3 ubiquitin ligase in T-cell skin diseases, revealing a progressive increase from benign inflammatory dermatoses to cutaneous T-cell lymphoma, suggesting its potential role in disease pathogenesis and as a therapeutic target.

    DOI: 10.1016/j.jid.2016.02.291
  10. Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells Experimental Hematology (2003) Thin

    Jak2 is constitutively activated in NPM/ALK-transformed cells and sustains proliferation while protecting against apoptosis; pharmacologic inhibition or genetic blockade of Jak2 reduces proliferation, induces apoptosis, and impairs Stat5-driven transcription, implicating the Jak…

    DOI: 10.1016/S0301-472X(03)00007-9
  11. MNT loss in MYC-driven B lymphoma cells enhances apoptosis, inhibits proliferation and increases sensitivity to cancer drugs Thin

    Loss of MNT in MYC-driven B-cell lymphomas triggers apoptosis via BIM/PUMA, reduces proliferation and promotes senescence in apoptosis-resistant cells, and greatly increases sensitivity to conventional chemotherapy and BH3 mimetics, pointing to MNT inhibition as a potential ther…

    DOI: 10.64898/2026.04.29.721758
  12. Apoptosis and Cell Proliferation Capacity in AKR Lymphoma Malignancy Variants Cancer Investigation (2000) Thin

    This study investigates the relationship between apoptosis and cell proliferation in various malignancy variants of AKR lymphoma, revealing unexpected trends in apoptotic cell content and the expression of apoptosis-related genes.

    DOI: 10.3109/07357900009012202
  13. Modes of action of anthelmintic drugs The Veterinary Journal (1997) Thin

    A comprehensive review of the cellular and molecular modes of action of major anthelmintic drugs across nematodes and other helminths, detailing nicotinic receptor agonists, GABA and glutamate-gated chloride channels, calcium permeability, microtubule disruption, protonophores, …

    DOI: 10.1016/s1090-0233(05)80005-x

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question